Citations

Clear

3042 citation(s) found for "Kumar, S".

Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation
Muchtar, Eli , Lacy, Martha Q. , Kapoor, Prashant , Hayman, Suzanne R. , Gonsalves, Wilson I. , Warsame, Rahma , Kourelis, Taxiarchis , Chakraborty, Rajshekhar , Russell, Stephen J. , Lust, John A., Lin, Yi , Zeldenrust, Steven R., Dingli, David , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Gonsalves, Wilson , Kourelis, Taxiarchis V, Russell, Stephen, Zeldenrust, Steven, Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Go, Ronald S. , Leung, Nelson , Rajkumar, S. Vincent , Gertz, Morie A. , Muchtar, E , Russell, Stephen J , Chakraborty, Rajshekhar , Dingli, David , Lin, Yi

Mayo Clinic

British Journal of Haematology | July 12, 2017 | Volume: 178 | Issue: 6 | Pages: 888-895

10.1111/bjh.14830 | PMID 28699650 Get It

SummaryThe significance of serum lactate dehydrogenase (LDH) in light chain (AL) amyloidosis has not been previously explored. We studied 1019 newly diagnosed patients and correlated the elevation of LDH above the upper limit of normal (ULN) with disease characteristics and outcome. Four hundred and nine patients had an LDH above ULN, representing 40% of the study population. Patients with an elevated LDH were older, were less likely to be male and had more extensive organ involvement compared to patients with a normal LDH. Patients with high LDH had greater cardiac and renal dysfunction. Elevated LDH was an independent prognostic marker for overall survival and for death within 6 months of diagnosis, but this was restricted to patients not eligible for stem cell transplant. Serum LDH may act as a marker for organ damage and should be explored as a potential marker for tissue healing and organ recovery.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Paludo, Jonas , LaPlant, Betsy, Halvorson, Alese E. , Kumar, Shaji , Hayman, Suzanne R. , Lust, John A., Kapoor, Prashant , Russell, Stephen J. , Dingli, David , Lin, Yi , Bergsagel, P. Leif , Sher, Taimur , Chanan‐Khan, Asher , Stewart, A. Keith, Reeder, Craig B. , Richardson, Paul G. , Lacy, Martha Q. , Bergsagel, P. Leif , Mikhael, Joseph R., LaPlant, Betsy R, Buadi, Francis K. , Chanan-Khan, Asher A., Mıkhael, Joseph , Gertz, Morie A. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I. , Fonseca, Rafaël , Roy, Vivek , Ailawadhi, Sikander , Richardson, Paul Gerard Guy , Rajkumar, S. Vincent , Paludo, Jonas , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

Blood | July 6, 2017 | Volume: 130 | Issue: 10 | Pages: 1198-1204

10.1182/blood-2017-05-782961 | PMID 28684537 Get It

Key Points PVD is an active combination in relapsed lenalidomide-refractory MM patients. PVD with weekly bortezomib offers a simpler, more convenient, and well-tolerated regimen option.
Intravenous Alteplase for Acute Stroke and Pulmonary Embolism in a Patient With Recent Abdominoplasty
Christiansen, Michael E., Kumar, Gyanendra , Mahabir, Raman C. , Helmers, Richard A. , O’Carroll, Cumara B. , Bendok, Bernard R.

Mayo Clinic

The Neurologist | June 22, 2017 | Volume: 22 | Issue: 4 | Pages: 150-152

10.1097/nrl.0000000000000139 | PMID 28644260 Get It

Introduction: Major surgery in the past 14 days is a relative contraindication to treatment of acute stroke with intravenous (IV) alteplase. The 2016 American Heart Association/American Stroke Association scientific statement discussing inclusion and exclusion criteria for alteplase in acute stroke allows for provider judgment citing a lack of evidence to support surgery as an absolute contraindication. Case Report: A 59-year-old woman presented with acute left hemiparesis, dysarthria, and acute respiratory failure. National Institutes of Health Stroke Scale was 17. Two days prior she underwent abdominoplasty and liposuction. Computed tomography angiogram of the head demonstrated acute occlusion of right M2, and computed tomography angiogram of the chest was positive for bilateral pulmonary emboli. After urgent consultation with the plastic surgery and neurosurgery teams, the patient was treated with IV alteplase followed by cerebral mechanical thrombectomy. This was complicated by surgical-site hemorrhage in the abdomen requiring operative intervention. Abdominal hemorrhage was controlled and the patient showed remarkable neurological recovery, later being discharged with no residual neurological deficits. Conclusions: Interdisciplinary collaboration can successfully inform the decision to treat acute ischemic stroke with IV alteplase in the setting of recent major surgery.
Hydrogen–Deuterium Exchange Mass Spectrometry Reveals Calcium Binding Properties and Allosteric Regulation of Downstream Regulatory Element Antagonist Modulator (DREAM)
Zhang, Jun , Craig, Theodore A., Kumar, Rajiv , Gross, Michael L. , Gross, Michael L , Li, Jing , Kumar, Rajiv

Mayo Clinic

Biochemistry | June 19, 2017 | Volume: 56 | Issue: 28 | Pages: 3523-3530

10.1021/acs.biochem.7b00100 | PMID 28627884 Get It

Abstract Downstream regulatory element antagonist modulator (DREAM) is an EF-hand Ca2+-binding protein that also binds to a specific DNA sequence, downstream regulatory elements (DRE), and thereby regulates transcription in a calcium-dependent fashion. DREAM binds to DRE in the absence of Ca2+ but detaches from DRE under Ca2+ stimulation, allowing gene expression. The Ca2+ binding properties of DREAM and the consequences of the binding on protein structure are key to understanding the function of DREAM. Here we describe the application of hydrogen–deuterium exchange mass spectrometry (HDX-MS) and site-directed mutagenesis to investigate the Ca2+ binding properties and the subsequent conformational changes of full-length DREAM. We demonstrate that all EF-hands undergo large conformation changes upon calcium binding even though the EF-1 hand is not capable of binding to Ca2+. Moreover, EF-2 is a lower-affinity site compared to EF-3 and -4 hands. Comparison of HDX profiles between wild-type DREAM and two EF-1 mutated constructs illustrates that the conformational changes in the EF-1 hand are induced by long-range structural interactions. HDX analyses also reveal a conformational change in an N-terminal leucine-charged residue-rich domain (LCD) remote from Ca2+-binding EF-hands. This LCD domain is responsible for the direct interaction between DREAM and cAMP response element-binding protein (CREB) and regulates the recruitment of the co-activator, CREB-binding protein. These long-range interactions strongly suggest how conformational changes transmit the Ca2+ signal to CREB-mediated gene transcription.
Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer
Muchtar, Eli , Kumar, Shaji , Magen, Hila , Gertz, Morie A. , Kumar, Shaji K , Gertz, Morie A , Muchtar, E

Mayo Clinic

Leukemia & Lymphoma | June 8, 2017 | Volume: 59 | Issue: 2 | Pages: 288-299

10.1080/10428194.2017.1334124 | PMID 28592156 Get It

Impact of concomitant dexamethasone dosing schedule on bortezomib‐induced peripheral neuropathy in multiple myeloma
Kumar, Shaji , Laubach, Jacob P. , Giove, Thomas J., Quick, Maureen, Neuwirth, Rachel, Yung, Godwin , Richardson, Paul G. , Kumar, Shaji K , Rajkumar, S. Vincent , Richardson, Paul Gerard Guy , Yung, Godwin

Mayo Clinic

British Journal of Haematology | June 7, 2017 | Volume: 178 | Issue: 5 | Pages: 756-763

10.1111/bjh.14754 | PMID 28591409 Get It

SummaryPeripheral neuropathy (PN) is the most troublesome adverse event associated with the proteasome inhibitor bortezomib. Studies suggest an inflammatory aetiology for bortezomib‐induced PN (BiPN) and it has been hypothesized that reducing inflammation with concomitant dexamethasone may reduce BiPN incidence and/or severity. We retrospectively analysed PN rates from 32 studies (2697 patients with previously untreated multiple myeloma) incorporating bortezomib and differing dexamethasone schedules: partnered dosing (days of and after bortezomib), weekly dosing, and other dosing schedules (e.g. days 1–4, 8–11). Pooled overall PN rates were 45·5%, 63·9%, and 47·5%, respectively, with 5·3%, 11·0%, and 9·6% grade ≥3. Adjusting for potential confounders (age, gender, presence of thalidomide, bortezomib treatment duration), PN rates in patients on partnered dosing schedules appeared lower than in patients on weekly or other dosing schedules. Analyses conducted using patient‐level data suggest that cumulative dexamethasone dose, a potential confounding factor, is unlikely to have influenced the analyses. Findings were similar in a separate pooled analysis excluding data from regimens incorporating thalidomide, when pooled overall PN rates were 50·1%, 63·9%, and 48·3%, respectively, with 4·2%, 11·0%, and 8·6% grade ≥3. These findings suggest that partnered dexamethasone dosing may result in less severe BiPN compared with alternative dexamethasone dosing schedules.
Tympanostomy Tube Placement in Children Using a Single‐Pass Tool with Moderate Sedation
Cofer, Shelagh A. , Meyer, Abby, Yoon, Daniel, Beebe, David S., Castro, Chandra, Rimell, Frank L., Belani, Kumar G. , Cofer, Shelagh, Meyer, Abby C.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 6, 2017 | Volume: 157 | Issue: 3 | Pages: 533-535

10.1177/0194599817707178 | PMID 28585495 Get It

Insertion of tympanostomy tubes is a common elective pediatric surgical procedure and is typically performed under general anesthesia. The potential to reduce general anesthetic requirements for young children has led to increased interest in alternatives for tympanostomy tube placement. A tympanostomy tube system, developed to enable tympanostomy tube placement in a single pass on conscious patients under moderate sedation, was evaluated. A prospective study on 128 children and 253 tympanostomy tube placements conducted at 4 centers in the United States demonstrated an 88.3% success rate in performing the procedure under moderate sedation with adverse events within normal rates reported in the literature. The feasibility of completing tympanostomy tube placement under moderate sedation enables avoidance of general anesthesia and provides additional choices to physicians and parents.
Effect of Obstructive Sleep Apnea Treatment on Lipids in Obese Children
Amini, Zarlasht, Kotagal, Suresh , Lohse, Christine M. , Lloyd, Robin M. , Sriram, Swetha, Kumar, Seema , Lohse, Christine, Lloyd, Robin, Kumar, Seema

Mayo Clinic

Children | June 1, 2017 | Volume: 4 | Issue: 6 | Pages: 44

10.3390/children4060044 | PMID 28587180 Get It

Obesity in children is associated with several co-morbidities including dyslipidemia. Obstructive sleep apnea (OSA) is commonly seen in obese children. In adults, diagnosis of OSA independent of obesity is associated with cardiometabolic risk factors including dyslipidemia. There is limited data on the impact of treatment of OSA on lipids in children. The objective of the study was to examine the impact of treatment of OSA on lipids in 24 obese children. Methods: Seventeen children were treated with continuous positive airway pressure (CPAP) and five underwent adenotonsillectomy. Mean apnea hypopnea index prior to treatment was 13.0 + 12.1 and mean body mass index (BMI) was 38.0 + 10.6 kg/m2. Results: Treatment of OSA was associated with improvement in total cholesterol (mean change = −11 mg/dL, p < 0.001), and low-density lipoprotein cholesterol (mean change = –8.8 mg/dL, p = 0.021). Conclusion: Obese children should be routinely screened for OSA, as treatment of OSA favorably influences lipids and therefore decreases their cardiovascular risk.
Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain
Swaminathan, Suresh Kumar, Ahlschwede, Kristen M. , Sarma, Vidur , Curran, Geoffry L., Omtri, Rajesh S. , Decklever, Teresa, Lowe, Val J. , Poduslo, Joseph F., Kandimalla, Karunya K. , Kandimalla, Karunya K

Mayo Clinic

Journal of Cerebral Blood Flow & Metabolism | June 1, 2017 | Volume: 38 | Issue: 5 | Pages: 904-918

10.1177/0271678x17709709 | PMID 28569090 Get It

Impaired brain clearance of amyloid-beta peptides (Aβ) 40 and 42 across the blood–brain barrier (BBB) is believed to be one of the pathways responsible for Alzheimer’s disease (AD) pathogenesis. Hyperinsulinemia prevalent in type II diabetes was shown to damage cerebral vasculature and increase Aβ accumulation in AD brain. However, there is no clarity on how aberrations in peripheral insulin levels affect Aβ accumulation in the brain. This study describes, for the first time, an intricate relation between plasma insulin and Aβ transport at the BBB. Upon peripheral insulin administration in wild-type mice: the plasma clearance of Aβ40 increased, but Aβ42 clearance reduced; the plasma-to-brain influx of Aβ40 increased, and that of Aβ42 reduced; and the clearance of intracerebrally injected Aβ40 decreased, whereas Aβ42 clearance increased. In hCMEC/D3 monolayers (in vitro BBB model) exposed to insulin, the luminal uptake and luminal-to-abluminal permeability of Aβ40 increased and that of Aβ42 reduced; the abluminal-to-luminal permeability of Aβ40 decreased, whereas Aβ42 permeability increased. Moreover, Aβ cellular trafficking machinery was altered. In summary, Aβ40 and Aβ42 demonstrated distinct distribution kinetics in plasma and brain compartments, and insulin differentially modulated their distribution. Cerebrovascular disease and metabolic disorders may disrupt this intricate homeostasis and aggravate AD pathology.
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma
Ghosh, Toshi, Gonsalves, Wilson I. , Jevremović, Dragan , Dingli, David , Timm, Michael, Morice, William G. , Kapoor, Prashant , Kourelis, Taxiarchis , Lacy, Martha Q. , Hayman, Suzanne R. , Lin, Yi , Russell, Stephen J. , Lust, John A., Zeldenrust, Steven R., Warsame, Rahma , Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Timm, Michael M, Kourelis, Taxiarchis V, Buadi, Francis K. , Leung, Nelson , Go, Ronald S , Warsame, Rahma , Dispenzieri, Angela , Morice, William George , Leung, Nelson , Go, Ronald S. , Gertz, Morie A. , Rajkumar, S. Vincent , Gonsalves, Wilson , Russell, Stephen J , Jevremovic, Dragan , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | June 1, 2017 | Volume: 92 | Issue: 9 | Pages: No page available

10.1002/ajh.24807 | PMID 28568244 Get It

AbstractPrior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7‐color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with ≥5% pPCs (P = .0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5% pPCs (P = .019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with ≥5% pPCs (P = .033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard‐risk cytogenetics, who have a particularly adverse outcome.